CD8A and neoplasm: It has been widely accepted that the treatment with ICIs results in improved survival in patients with dMMR/MSI tumors due to the high tumor mutation burden and neoantigen load, leading to immune cell infiltration, including CD8+ T cells, in the TME [13,14].